Selank's Immune and Interferon Research
Selank (a synthetic heptapeptide, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, sometimes marketed as a "peptide nootropic" or research chemical) is not FDA-approved for any indication, human or veterinary. It is not on the FDA's 503A bulk drug substances list used for compounding. See the FDA Peptide Status Tracker for current regulatory status across the peptide category. Nothing in this article should be read as a claim of approval, legality for compounding, or clinical efficacy.
Why does Selank get linked to the immune system at all?
Selank was designed as a synthetic analog extending tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of immunoglobulin G. Tuftsin has a long, separate research history as a phagocytosis-stimulating and immune-modulating fragment, which is why some marketing material for Selank borrows tuftsin's reputation and implies that Selank inherits tuftsin's immune actions. Structural relation is a real fact. Inherited pharmacology is not automatic, and extending or modifying a peptide backbone can change receptor affinity, degradation rate, and downstream signaling in ways that make the parent molecule's data non-transferable. For background on Selank's structure and origin, see what is Selank and the mechanism overview.
What does the current immune and interferon literature actually study?
The active literature on interferon signaling, cGAS-STING pathway activity, and immune microenvironments is substantial, but it is about specific diseases and specific molecules, not about Selank. Recent work in this space includes STING agonist adjuvants engineered for anti-infective and antitumor immunity (cGAMP-liposome adjuvant research), STING-axis mechanisms in pancreatic cancer's immunosuppressive microenvironment (Lin28b-STING axis in pancreatic cancer), and cGAS-STING/NF-κB signaling implicated in neuroinflammation and depression-like behavior in animal models (shikonin and microglial polarization). Interferon-responsive microglial regulators have been mapped by genome-wide screening (CRISPRi screen of interferon-responsive microglia), and epigenetic reprogramming of circulating immune cells during acute COVID-19 has been profiled directly in patients (H3K4me3 profiling in acute COVID-19). Neutrophil extracellular traps and STING-mediated ferroptosis have been studied after traumatic brain injury (NETs and STING-mediated ferroptosis after TBI), and immune-mediated inflammation is a documented driver in atherosclerosis progression (inflammation and immune mechanisms in atherosclerosis).
This is what real, current immune-pathway research looks like: narrow, mechanistic, tied to a specific disease model or patient population, and reported with the actual pathway named. None of it mentions Selank, tuftsin, or any tuftsin analog. It is included here only to show the field's level of specificity, and to make the contrast obvious: broad phrases like "supports immune function" do not map onto how this research is actually conducted or reported.
Is there any human or animal data on Selank and immune markers?
Not in the evidence available for this article. There is no cited study measuring Selank's effect on cytokines, interferon levels, phagocytic activity, or any immune biomarker, in humans or animals. If such studies exist elsewhere, they should be evaluated on their own species, dose, and route before any claim is made, and a claim built on them should say so explicitly rather than resting on tuftsin's older, separate literature. Readers should treat "Selank has immune benefits" as an unverified claim, not an established one, until a study of Selank itself is identified and reviewed.
How should you weigh a structural-relative argument like this?
Evidence-chain reliability map for "Selank inherits tuftsin's immune effects"
| Link in the argument | What is actually established | Confidence this link holds |
|---|---|---|
| Tuftsin is a naturally occurring immune-modulating peptide | Long-standing, separate literature (not in this article's source set) | Not evaluated here; assume it needs its own review |
| Selank is a synthetic peptide built by extending the tuftsin sequence | Structural fact, consistent with how Selank is described in the literature | Established |
| Structural relation to tuftsin means Selank shares tuftsin's receptor binding | Not demonstrated in any cited source | Not established |
| Selank has been tested for immune or interferon effects | No study in the available evidence base does this | Not established |
| Modern cGAS-STING/interferon research supports "Selank boosts immunity" | These studies exist but study unrelated molecules and diseases | Irrelevant to Selank; do not cite as support |
Use this table the way you would use it for any peptide sold on lineage rather than data: each row has to hold on its own. A true first row and a true second row do not make the third row true. If a product page or forum cites "Selank" and an immune claim in the same sentence, ask what specific study is being cited, in what species, at what dose, and whether it studied Selank or a different molecule in the same family.
What is established, what is plausible, and what is not established
Established: Selank's structural derivation from tuftsin, and Selank's lack of FDA approval for any use. Plausible but unproven: that Selank retains some fraction of tuftsin's described immune activity, given shared sequence elements. Not established: any specific immune, interferon, or cytokine effect of Selank in humans or animals, based on the sources available here. Readers using Selank from compounded or research-chemical sources for anything related to immune support should treat that use as unverified extrapolation, not as guideline-supported or trial-supported practice.
When should this prompt a conversation with a clinician instead of self-directed use?
If you are considering Selank for an immune-related reason (recurrent infections, autoimmune symptoms, post-viral fatigue, or similar), that is a reason to see a clinician for an actual diagnostic workup, not a reason to self-treat with an unapproved peptide with no immune data behind it. Immune and inflammatory symptoms have many causes that need real evaluation, and delaying that evaluation to try an unverified peptide carries its own risk. For general safety and side-effect information unrelated to this immune question, see Selank side effects and safety; for how Selank is actually regulated in the US, see Selank FDA status; and for a broader look at how strong the human evidence is across Selank's claimed uses, see Selank evidence quality.